Denosumab biosimilar (Alphamab)

地舒单抗生物类似药（康宁杰瑞）

Report date: 2024/09/09 17:55:01

Base Information

Drug NameDenosumab biosimilar (Alphamab)
Drug Alias Name重组全人源抗RANKL单克隆抗体注射液（康宁杰瑞）重组全人源抗RANKL单抗注射液（康宁杰瑞）KN-012
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis, Postmenopausal
Global Approved IndicationsOsteoporosis, Postmenopausal
Approved Indications in ChinaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryMainland China
Original Approved Date2024/09/03
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSuzhou Alphamab Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAlphamab Jilin Co LtdPhilippine Biological Technology (Jilin) ​​Co Ltd
Inactive CompaniesSuzhou Alphamab Co Ltd
Active IndicationsOsteoporosis, Postmenopausal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A